Lionsgate Studios Corp. filed a Form 8-K/A on November 6, 2026, amending its September 16, 2026 Current Report to disclose the company's decision to hold future advisory votes on executive compensation on an annual basis.
Tokyo Lifestyle Co., Ltd. filed a current report with the U.S. Securities and Exchange Commission on November 6, 2026, disclosing the convocation of an Extraordinary General Meeting of Shareholders scheduled for November 30, 2026, in Tokyo, Japan.
Dutch Bros Inc. filed a Form 8-K on November 6, 2026, disclosing that Chief Legal Officer Victoria Tullett notified the company on November 4, 2026 of her decision to retire in 2027, and that Kira Druyan has been appointed as the new Chief Legal …
9F Inc. filed a Form 6-K with the SEC on November 6, 2026, reporting unaudited financial results for the six months ended June 30, 2026, disclosing a sharp decline in total net revenues alongside a large increase in net income driven by unrealized investment …
Knight-Swift Transportation Holdings Inc. filed an 8-K on November 6, 2026, disclosing the appointment of Richard Howard to its Board of Directors effective November 4, 2026, and the declaration of a quarterly cash dividend of $0.20 per share.
Fifth Era Acquisition Corp I filed a Form 8-K on November 6, 2026, disclosing that Nasdaq granted the company an extension of time to regain compliance with the Minimum Total Holders Requirement after finding it deficient on September 14, 2026.
InflaRx N.V. filed a Form 6-K on November 6, 2026, reporting the peer-reviewed publication of first-in-human Phase 1 clinical data for its oral C5aR1 inhibitor izicopan, formerly known as INF904.
Central Puerto S.A. filed a Form 6-K on November 6, 2026, disclosing the automatic cancellation of 2,299,993 treasury shares under Argentine Capital Markets Law No. 26,831, reducing the company's share capital to ARS 1,511,470,229.
Tarun Manroa, Executive Vice President and Chief Operating Officer of Magnera Corp, filed a Form 4 on November 6, 2026, disclosing the vesting of restricted stock units and a related tax-withholding transaction dated November 4, 2026.
Jason Pitofsky, SVP Controller at Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on November 6, 2026, disclosing option exercises and open-market sales of common stock that all occurred on November 4, 2026.